Erika Pietrolongo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5416327/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	1.4	148
2	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	3.7	140
3	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	4.5	100
4	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
5	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679.	1.1	67
6	Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale. PLoS ONE, 2013, 8, e66127.	1.1	52
7	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44
8	Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments. PLoS ONE, 2013, 8, e60721.	1.1	44
9	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52.	0.8	39
10	The Kurtzke EDSS rank stability increases 4â€years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	0.9	37
11	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.3	37
12	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	1.4	36
13	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.3	35
14	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	1.1	35
15	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
16	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
17	Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations. PLoS ONE, 2015, 10, e0127734.	1.1	31
18	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. Frontiers in Psychology, 2017, 8, 2216.	1.1	30

Erika Pietrolongo

#	Article	IF	CITATIONS
19	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 893.	1.0	28
20	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184.	0.7	28
21	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. Multiple Sclerosis Journal, 2010, 16, 1237-1247.	1.4	27
22	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	1.1	21
23	Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center. Multiple Sclerosis and Related Disorders, 2020, 38, 101504.	0.9	19
24	Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. International Journal of Clinical Practice, 2012, 66, 504-514.	0.8	17
25	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	0.9	17
26	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246.	0.7	17
27	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	0.8	17
28	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open, 2017, 7, e017254.	0.8	16
29	Implementation of the â€~Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. Multiple Sclerosis Journal, 2014, 20, 1234-1243.	1.4	14
30	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMSâ€Trial. Health Expectations, 2014, 17, 36-48.	1.1	12
31	Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 813-815.	1.4	11
32	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866.	1.4	11
33	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. Quality of Life Research, 2016, 25, 2755-2763.	1.5	10
34	Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. Health Expectations, 2016, 19, 437-447.	1.1	10
35	Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. PLoS ONE, 2020, 15, e0228587.	1.1	9
36	Assessing measurement invariance of MSQOL-54 across Italian and English versions. Quality of Life Research, 2020, 29, 783-791.	1.5	4

Erika Pietrolongo

#	Article	IF	CITATIONS
37	The minimal neuropsychological assessment of MS patients (MACFIMS): normative data of the Italian population. Neurological Sciences, 2020, 41, 1489-1496.	0.9	3
38	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. Health and Quality of Life Outcomes, 2021, 19, 224.	1.0	2
39	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. Journal of the Neurological Sciences, 2020, 417, 117064.	0.3	1
40	Data of safety in a single-center alemtuzumab treated population. Data in Brief, 2020, 29, 105341.	0.5	1
41	Role preferences in treatment decisions of MS patients in Italy. Journal of the Neurological Sciences, 2015, 357, e316.	0.3	0
42	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889.	0.9	0
43	Title is missing!. , 2020, 15, e0228587.		0
44	Title is missing!. , 2020, 15, e0228587.		0
45	Title is missing!. , 2020, 15, e0228587.		0
46	Title is missing!. , 2020, 15, e0228587.		0